【計畫徵求】中清外泌體平台計畫構想書即日起至114年7月10日中午收件截止

中清外泌體平台計畫徵求說明

  • 計畫目標：

為推動中國醫藥大學與清華大學在外泌體新藥領域的深度合作，聚焦於優化現行中醫大外泌體產品之開發，將清華團隊技術導入現有產品線，提升製程效率與藥物設計，集中資源發揮最大效益。

為此，中清外泌體平台誠摯徵求雙方有志於外泌體應用的研究團隊，組成以產品導向為核心的4組計畫團隊，針對現階段的研發挑戰提出具體解方，並規劃合作內容與經費需求，每組計畫經費上限共2000萬，為期4年。

  • 計畫期程：自115年1月1日至118年12月31日。
  • 計畫經費：每組團隊預計由4位主持人共同執行計畫，每位主持人可編列4年共500萬元的預算額度（具體金額視核定經費而定）。
  • 申請時間：即日起至114年7月10日中午12點止，逾期不予受理。
  • 申請方式：由清大個別教師提出申請。請於截止期限前將附件構想書寄至yfwu@mx.nthu.edu.tw完成提案收件，中國醫藥大學會根據構想書遴選適合團隊，於八月初公告結果。
  • 其他說明：

此計畫現階段的目標為徵求潛在合作團隊，中國醫藥大學將以徵求結果名單作為向上申請經費的依據。待經費核定後，雙方將簽署合作協議，並明訂研究成果的智慧財產權歸屬原則。屆時，各計畫主持人可依自身權益考量是否加入合作。敬請於申請時留意計畫推動過程中的不確定性。

  • 本案聯絡人：吳小姐 (#31252)
  • 計畫徵求重點：

第一組計畫

  • Objective: To co-develop a cutting-edge human iPSC-derived Brain-on-a-Chip (BoC) and Peripheral Neuron-on-a-Chip (PNoC) platform, integrating multi-lineage human neural cells with disease-specific applications.
  • Scope & Features:
    1. Brain-on-a-Chip: Incorporating brain organoid, blood-brain barrier (BBB) components (endothelial-pericyte-astrocyte tri-culture), dynamic 3D synaptic networks, and real-time electrophysiological readouts. Suitable for modeling neurodegenerative diseases such as AD/PD.
    2. Peripheral Neuron-on-a-Chip: Incorporating Schwann cells with sensory/motor neurons, enabling drug screening for neurotoxicity and nerve regeneration.
    3. Core technologies: 3D bioprinting, microfluidics-based fluid/nutrient gradient control, embedded biosensors.
  • Deliverables:
    1. Disease-specific BoC/PNoC prototypes.
    2. Drug screening datasets for neuroprotective agents.
    3. Cross-validation with CMUH’s therapeutic sEVs, and PD/AD animal models.

第二組計畫

  • Objective: To develop a novel LNP-sEVs hybrid vesicle system for the efficient, scalable, and targeted delivery of RNA and small-molecule therapeutics.
  • Scope & Features:
    1. LNP-exosome fusion: Hybrid nanovesicles integrating FDA-compliant LNPs with naïve or engineered sEVs
    2. Post-loading optimization: High-efficiency encapsulation for both hydrophilic (e.g., mRNA, peptides) and hydrophobic drugs.
    3. EV delivery platform via Optoelectronic Technology
    4. Core technologies: LNP, naïve or engineered sEVs, loading platform
  • Deliverables:
    1. Stable hybrid vesicle formulations.
    2. In vivo biodistribution and efficacy data.
    3. Cross-validation with CMUH’s animal models
    4. GMP-relevant production framework.

第三組計畫

  • Objective: Development of a Scalable Manufacturing Platform for Nucleic Acid-Loaded Extracellular Vesicles Using Functionalized Microcarriers, Photoporation, and Membrane Surface Engineering.
  • Scope & Features:
  1. Design and optimization of functional PEGS-based microcarriers to enhance stem cell adhesion and EV yield
  2. Application of photoporation technology for efficient nucleic acid loading into EVs
  3. Surface engineering of EV membranes via DSPE conjugation/click chemistry
  4. Integration of core technologies to establish a scalable and robust EV production platform
  • Deliverables:
    1. Develop a novel microcarriers to enhance EV yield
    2. Establishment of a technology to enhance nucleic acid loading
    3. Foundation for scalable EV membrane surface engineering

第四組計畫

  • Objective: Development of oral transferrin-extracellular vesicle capsule dosage form to induce intestinal endocytosis and brain-targeted delivery of brain-active small molecule drugs or brain-derived mRNA in highly effective targeted treatment of depression
  • Scope & Features:
    1. Development of oral EV capsule dosage
    2. Transferrin modification to induce intestinal endocytosis.
    3. Exploration of the delivery mechanism of EV across the gut-brain axis
    4. Small molecule drug or mRNA loading technology
    5. Antidepressant treatment target and mechanism verification
  • Deliverables:
    1. Oral EV Capsule Formulation
    2. Transferrin-Modified EVs for Intestinal Uptake
    3. Gut-Brain Axis Delivery Model
    4. Drug/mRNA Loading into EVs
    5. Mechanistic Validation of Antidepressant Action